We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Swiss Helvetia Fund Inc | NYSE:SWZ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.04 | -0.53% | 7.52 | 7.5499 | 7.51 | 7.53 | 9,599 | 21:25:01 |
The Swiss Helvetia Fund, Inc.
|
|
Executive Offices
|
|
615 East Michigan Street
|
|
Milwaukee, WI 53202
|
|
(800) 730-2932
|
|
A Swiss Investments Fund
|
Semi-Annual Report
|
www.swzfund.com
|
|
For the Six Months Ended
|
|
June 30, 2023
|
Net asset value returns
|
1 year
|
5 years
|
10 years
|
The Swiss Helvetia Fund, Inc.
|
18.67%
|
8.43%
|
7.29%
|
Market price returns
|
|||
The Swiss Helvetia Fund, Inc.
|
12.18%
|
6.98%
|
7.54%
|
Index returns
|
|||
Swiss Performance Index
|
14.51%
|
9.78%
|
8.04%
|
Share price as of 6/30/2023
|
|||
Net asset value
|
|
||
Market price
|
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — 96.28%
|
|||||||||||
Advertising — 0.48%
|
|||||||||||
8,100
|
DKSH Holding AG
|
$
|
602,532
|
0.48
|
%
|
||||||
An international
|
|||||||||||
marketing and services
|
|||||||||||
group. The company offers
|
|||||||||||
a comprehensive package
|
|||||||||||
of services that includes
|
|||||||||||
organizing and running
|
|||||||||||
the entire value chain
|
|||||||||||
for any product.
|
|||||||||||
(Cost $624,087)
|
|||||||||||
602,532
|
0.48
|
%
|
|||||||||
Banks — 2.61%
|
|||||||||||
895
|
St Galler Kantonalbank AG
|
485,190
|
0.38
|
%
|
|||||||
Offers retail and
|
|||||||||||
commercial banking
|
|||||||||||
as well as private and
|
|||||||||||
institutional banking.
|
|||||||||||
Also provides asset
|
|||||||||||
management and financial
|
|||||||||||
planning services.
|
|||||||||||
(Cost $439,441)
|
|||||||||||
138,800
|
UBS Group AG
|
2,807,339
|
2.23
|
%
|
|||||||
Provides retail banking,
|
|||||||||||
corporate and institutional
|
|||||||||||
banking, wealth
|
|||||||||||
management, asset
|
|||||||||||
management and
|
|||||||||||
investment banking.
|
|||||||||||
(Cost $1,884,953)
|
|||||||||||
3,292,529
|
2.61
|
%
|
|||||||||
Biotechnology — 2.63%
|
|||||||||||
41,308
|
Idorsia Ltd.1
|
297,811
|
0.24
|
%
|
|||||||
Researches, develops,
|
|||||||||||
and manufactures
|
|||||||||||
pharmaceutical, biological,
|
|||||||||||
and diagnostic products.
|
|||||||||||
(Cost $1,141,326)
|
|||||||||||
5,062
|
Lonza Group AG
|
3,018,019
|
2.39
|
%
|
|||||||
Produces organic fine
|
|||||||||||
chemicals, biocides,
|
|||||||||||
active ingredients, and
|
|||||||||||
biotechnology products.
|
|||||||||||
(Cost $2,925,070)
|
|||||||||||
3,315,830
|
2.63
|
%
|
|||||||||
Building Materials — 3.41%
|
|||||||||||
820
|
Forbo Holding AG
|
1,176,862
|
0.93
|
%
|
|||||||
Produces floor coverings,
|
|||||||||||
adhesives and belts for
|
|||||||||||
conveying and power
|
|||||||||||
transmission.
|
|||||||||||
(Cost $1,292,481)
|
|||||||||||
1,097
|
Geberit AG
|
573,974
|
0.46
|
%
|
|||||||
Manufactures and supplies
|
|||||||||||
water supply pipes and
|
|||||||||||
fittings, installation, and
|
|||||||||||
drainage and flushing
|
|||||||||||
systems such as visible
|
|||||||||||
cisterns other sanitary
|
|||||||||||
systems for the
|
|||||||||||
commercial and residential
|
|||||||||||
construction markets.
|
|||||||||||
(Cost $482,481)
|
|||||||||||
8,912
|
Sika AG
|
2,547,140
|
2.02
|
%
|
|||||||
Manufactures construction
|
|||||||||||
materials, producing
|
|||||||||||
concrete and mixtures,
|
|||||||||||
mortar, sealants and
|
|||||||||||
adhesives, tooling resins,
|
|||||||||||
anti-static industrial
|
|||||||||||
flooring, and acoustic
|
|||||||||||
materials. The company
|
|||||||||||
serves customers
|
|||||||||||
worldwide.
|
|||||||||||
(Cost $1,731,659)
|
|||||||||||
4,297,976
|
3.41
|
%
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Chemicals — 1.50%
|
|||||||||||
570
|
Givaudan SA
|
$
|
1,889,063
|
1.50
|
%
|
||||||
Manufactures and markets
|
|||||||||||
fragrances and flavors
|
|||||||||||
from natural and synthetic
|
|||||||||||
ingredients. The Company
|
|||||||||||
sells its products to
|
|||||||||||
manufactures of perfumes,
|
|||||||||||
beverages, prepared foods,
|
|||||||||||
and consumer goods.
|
|||||||||||
(Cost $1,865,973)
|
|||||||||||
1,889,063
|
1.50
|
%
|
|||||||||
Computers — 1.82%
|
|||||||||||
31,300
|
Logitech International SA
|
1,862,641
|
1.48
|
%
|
|||||||
Engages in the development
|
|||||||||||
and marketing of hardware
|
|||||||||||
and software products that
|
|||||||||||
enable or enhance digital
|
|||||||||||
navigation, music and video
|
|||||||||||
entertainment, gaming,
|
|||||||||||
social networking and audio
|
|||||||||||
and video communication.
|
|||||||||||
(Cost $424,372)
|
|||||||||||
22,000
|
SoftwareONE Holding AG
|
435,992
|
0.34
|
%
|
|||||||
Provides IT services. The
|
|||||||||||
Company offers cloud
|
|||||||||||
computing, portfolio
|
|||||||||||
management, procurement,
|
|||||||||||
unified communication,
|
|||||||||||
and other related solutions.
|
|||||||||||
(Cost $400,813)
|
|||||||||||
2,298,633
|
1.82
|
%
|
|||||||||
Diversified Financial Services — 3.85%
|
|||||||||||
24,600
|
Julius Baer Group Ltd.
|
1,549,169
|
1.23
|
%
|
|||||||
Provides private banking
|
|||||||||||
services. The company
|
|||||||||||
advises on wealth
|
|||||||||||
management, financial
|
|||||||||||
planning and investments;
|
|||||||||||
offers mortgage and other
|
|||||||||||
lending, foreign exchange,
|
|||||||||||
securities trading, custody
|
|||||||||||
and execution services.
|
|||||||||||
(Cost $1,180,871)
|
|||||||||||
10,000
|
Swissquote Group
|
||||||||||
Holding SA
|
2,075,672
|
1.64
|
%
|
||||||||
Through its subsidiaries,
|
|||||||||||
offers online financial
|
|||||||||||
services. The company
|
|||||||||||
operates an online trading
|
|||||||||||
system which offers
|
|||||||||||
customers real-time
|
|||||||||||
securities quotes on the
|
|||||||||||
Swiss Stock Exchange.
|
|||||||||||
(Cost $986,509)
|
|||||||||||
13,408
|
VZ Holding AG
|
1,231,920
|
0.98
|
%
|
|||||||
Provides independent
|
|||||||||||
financial advice to private
|
|||||||||||
individuals and companies.
|
|||||||||||
The company consults on
|
|||||||||||
investment, tax and
|
|||||||||||
inheritance planning and
|
|||||||||||
provides advice regarding
|
|||||||||||
insurance products and
|
|||||||||||
coverage.
|
|||||||||||
(Cost $438,472)
|
|||||||||||
4,856,761
|
3.85
|
%
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Electric — 2.06%
|
|||||||||||
14,700
|
BKW AG
|
$
|
2,596,099
|
2.06
|
%
|
||||||
Provides energy supply
|
|||||||||||
services. The company
|
|||||||||||
focuses on the production,
|
|||||||||||
transportation, trading and
|
|||||||||||
sale of energy. In addition
|
|||||||||||
to energy supply, the
|
|||||||||||
company also develops,
|
|||||||||||
implements and operates
|
|||||||||||
energy solutions
|
|||||||||||
for its clients.
|
|||||||||||
(Cost $1,177,241)
|
|||||||||||
2,596,099
|
2.06
|
%
|
|||||||||
Electronic Components & Equipment — 2.15%
|
|||||||||||
43,024
|
ABB Ltd.
|
1,691,817
|
1.34
|
%
|
|||||||
Provides power and
|
|||||||||||
automation technologies.
|
|||||||||||
The company operates
|
|||||||||||
under segments that include
|
|||||||||||
power products, power
|
|||||||||||
systems, automation
|
|||||||||||
products, process
|
|||||||||||
automation, and robotics.
|
|||||||||||
(Cost $872,256)
|
|||||||||||
3,967
|
Comet Holding AG
|
1,012,757
|
0.81
|
%
|
|||||||
Develops, produces, and
|
|||||||||||
distributes components
|
|||||||||||
and systems for x-ray tubes,
|
|||||||||||
vacuum condensers, and
|
|||||||||||
radio frequency, as well as
|
|||||||||||
other medical products.
|
|||||||||||
(Cost $1,012,150)
|
|||||||||||
2,704,574
|
2.15
|
%
|
|||||||||
Food — 21.40%
|
|||||||||||
1,480,000
|
Aryzta AG1
|
2,454,949
|
1.95
|
%
|
|||||||
Produces and retails
|
|||||||||||
specialty bakery products.
|
|||||||||||
The Company produces
|
|||||||||||
French breads, pastries,
|
|||||||||||
continental breads,
|
|||||||||||
confections, artisan breads,
|
|||||||||||
homestyle lunches,
|
|||||||||||
viennoiserie, patisserie,
|
|||||||||||
cookies, pizza, appetizers,
|
|||||||||||
and sweet baked goods.
|
|||||||||||
(Cost $1,589,760)
|
|||||||||||
630
|
Barry Callebaut AG
|
1,216,129
|
0.96
|
%
|
|||||||
Manufactures cocoa
|
|||||||||||
and chocolate products.
|
|||||||||||
The Company markets
|
|||||||||||
to industrial food
|
|||||||||||
manufacturers, chocolatiers,
|
|||||||||||
pastry chefs, bakers, and
|
|||||||||||
retailers globally.
|
|||||||||||
(Cost $1,230,486)
|
|||||||||||
193,837
|
Nestle SA
|
23,312,872
|
18.49
|
%
|
|||||||
One of the world’s largest
|
|||||||||||
food and beverage
|
|||||||||||
processing companies.
|
|||||||||||
(Cost $12,557,687)
|
|||||||||||
26,983,950
|
21.40
|
%
|
|||||||||
Healthcare-Products — 6.07%
|
|||||||||||
26,357
|
Alcon, Inc.
|
2,183,037
|
1.73
|
%
|
|||||||
Manufactures eye care
|
|||||||||||
products. The company
|
|||||||||||
produces and markets
|
|||||||||||
vitreoretinal and cataract
|
|||||||||||
surgery, contact lenses,
|
|||||||||||
and refractive technology
|
|||||||||||
products.
|
|||||||||||
(Cost $1,752,716)
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Healthcare-Products — (continued)
|
|||||||||||
125,416
|
Eyesense AG, Series A1,2,3
|
$
|
50,466
|
0.04
|
%
|
||||||
A spin-out from Ciba
|
|||||||||||
Vision AG. Develops novel
|
|||||||||||
ophthalmic self- diagnostic
|
|||||||||||
systems for glucose
|
|||||||||||
monitoring of diabetes
|
|||||||||||
patients.
|
|||||||||||
(Cost $3,007,048)
|
|||||||||||
5,990
|
Medacta Group SA
|
815,494
|
0.65
|
%
|
|||||||
Produces and distributes
|
|||||||||||
medical devices. The
|
|||||||||||
company develops,
|
|||||||||||
manufactures, and
|
|||||||||||
distributes orthopedic
|
|||||||||||
and neurosurgical
|
|||||||||||
medical devices.
|
|||||||||||
(Cost $627,328)
|
|||||||||||
6,848
|
SKAN Group AG
|
589,388
|
0.47
|
%
|
|||||||
Provides health care
|
|||||||||||
supplies. The Company
|
|||||||||||
offers isolators, cleanroom
|
|||||||||||
devices, and decontamination
|
|||||||||||
processes for the aseptic
|
|||||||||||
production of the
|
|||||||||||
biopharmaceutical products.
|
|||||||||||
(Cost $530,142)
|
|||||||||||
3,855
|
Sonova Holding AG
|
1,026,391
|
0.81
|
%
|
|||||||
Designs and produces
|
|||||||||||
wireless analog and
|
|||||||||||
digital in-the-ear and
|
|||||||||||
behind-the-ear hearing aids
|
|||||||||||
and miniaturized voice
|
|||||||||||
communications systems.
|
|||||||||||
(Cost $632,400)
|
|||||||||||
221,085
|
Spineart SA1,2,3
|
1,309,731
|
1.04
|
%
|
|||||||
Designs and markets an
|
|||||||||||
innovative full range of
|
|||||||||||
spine products, including
|
|||||||||||
fusion and motion
|
|||||||||||
preservation devices,
|
|||||||||||
focusing on easy to implant
|
|||||||||||
high-end products to
|
|||||||||||
simplify the surgical act.
|
|||||||||||
(Cost $1,554,486)
|
|||||||||||
4,382
|
Tecan Group AG
|
1,680,995
|
1.33
|
%
|
|||||||
Manufactures and
|
|||||||||||
distributes laboratory
|
|||||||||||
automation components
|
|||||||||||
and systems. The products
|
|||||||||||
are mainly used by research
|
|||||||||||
and diagnostic laboratories.
|
|||||||||||
(Cost $401,116)
|
|||||||||||
7,655,502
|
6.07
|
%
|
|||||||||
Healthcare-Services — 0.72%
|
|||||||||||
11,300
|
Galenica AG
|
912,564
|
0.72
|
%
|
|||||||
Retails pharmaceutical
|
|||||||||||
products, and services
|
|||||||||||
customers in Switzerland.
|
|||||||||||
The Company offers
|
|||||||||||
health, beauty, and related
|
|||||||||||
products and services.
|
|||||||||||
(Cost $902,693)
|
|||||||||||
912,564
|
0.72
|
%
|
|||||||||
Industrials — 2.08%
|
|||||||||||
1,252
|
Belimo Holding AG1
|
624,426
|
0.50
|
%
|
|||||||
Manufactures heating,
|
|||||||||||
ventilation and air
|
|||||||||||
conditioning equipment.
|
|||||||||||
(Cost $144,479)
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Industrials — (continued)
|
|||||||||||
234,000
|
OC Oerlikon Corp. AG
|
$
|
1,165,488
|
0.92
|
%
|
||||||
Manufactures industrial
|
|||||||||||
equipment. The Company
|
|||||||||||
produces protective
|
|||||||||||
coatings for precision
|
|||||||||||
tools and components,
|
|||||||||||
equipment for textile
|
|||||||||||
production, and propulsion
|
|||||||||||
technology drive systems.
|
|||||||||||
(Cost $2,574,223)
|
|||||||||||
2,000
|
VAT Group AG
|
827,139
|
0.66
|
%
|
|||||||
Developer, manufacturer
|
|||||||||||
and supplier of vacuum
|
|||||||||||
valves, multi-valve modules
|
|||||||||||
and edge-welded bellows
|
|||||||||||
for use in semiconductor,
|
|||||||||||
display and solar panel
|
|||||||||||
manufacturing.
|
|||||||||||
(Cost $564,824)
|
|||||||||||
2,617,053
|
2.08
|
%
|
|||||||||
Insurance — 8.98%
|
|||||||||||
17,500
|
Baloise Holding AG
|
2,570,279
|
2.04
|
%
|
|||||||
Offers group and individual
|
|||||||||||
life, health, accident, liability
|
|||||||||||
property, and transportation
|
|||||||||||
insurance to customers in
|
|||||||||||
Europe. The Company also
|
|||||||||||
offers private banking and
|
|||||||||||
asset management services.
|
|||||||||||
(Cost $2,684,612)
|
|||||||||||
6,700
|
Helvetia Holding AG
|
906,164
|
0.72
|
%
|
|||||||
Provides a broad range
|
|||||||||||
of life, casualty, liability,
|
|||||||||||
accident and transportation
|
|||||||||||
insurance in Switzerland and
|
|||||||||||
in other European countries.
|
|||||||||||
The Company insures
|
|||||||||||
individuals, property such
|
|||||||||||
as vehicles and buildings,
|
|||||||||||
and consumer goods and
|
|||||||||||
personal belongings
|
|||||||||||
(Cost $579,944)
|
|||||||||||
4,130
|
Swiss Life Holding AG
|
2,414,341
|
1.91
|
%
|
|||||||
Provides life insurance
|
|||||||||||
and institutional
|
|||||||||||
investment management.
|
|||||||||||
(Cost $1,109,486)
|
|||||||||||
11,430
|
Zurich Insurance
|
||||||||||
Group AG
|
5,428,499
|
4.31
|
%
|
||||||||
Provides insurance-based
|
|||||||||||
financial services. The
|
|||||||||||
company offers general
|
|||||||||||
and life insurance products
|
|||||||||||
and services for individuals,
|
|||||||||||
small businesses,
|
|||||||||||
commercial enterprises,
|
|||||||||||
mid-sized and large
|
|||||||||||
corporations, and
|
|||||||||||
multinational companies.
|
|||||||||||
(Cost $3,698,494)
|
|||||||||||
11,319,283
|
8.98
|
%
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Machinery-Diversified — 0.50%
|
|||||||||||
26,500
|
Accelleron Industries AG
|
$
|
634,472
|
0.50
|
%
|
||||||
Develops, produces, and
|
|||||||||||
services turbochargers
|
|||||||||||
and large turbocharging
|
|||||||||||
components. The Company
|
|||||||||||
offers turbocharging
|
|||||||||||
technologies and
|
|||||||||||
optimization solutions for
|
|||||||||||
engines thereby reducing
|
|||||||||||
the environmental impact
|
|||||||||||
with less fuel emissions.
|
|||||||||||
(Cost $453,434)
|
|||||||||||
634,472
|
0.50
|
%
|
|||||||||
Metal Fabricate/Hardware — 1.23%
|
|||||||||||
11,806
|
SFS Group AG
|
1,554,515
|
1.23
|
%
|
|||||||
Provides automotive
|
|||||||||||
products, building and
|
|||||||||||
electronic components,
|
|||||||||||
flat roofing and solar
|
|||||||||||
fastening systems. The
|
|||||||||||
company operates
|
|||||||||||
production facilities in Asia,
|
|||||||||||
Europe and North America.
|
|||||||||||
(Cost $778,990)
|
|||||||||||
1,554,515
|
1.23
|
%
|
|||||||||
Packaging & Containers — 1.49%
|
|||||||||||
68,000
|
SIG Combibloc Group AG
|
1,875,862
|
1.49
|
%
|
|||||||
The company, through its
|
|||||||||||
subsidiaries, manufactures
|
|||||||||||
and produces bottling
|
|||||||||||
machines and systems for
|
|||||||||||
the food and beverage
|
|||||||||||
industries. The company
|
|||||||||||
serves customers worldwide.
|
|||||||||||
(Cost $746,444)
|
|||||||||||
1,875,862
|
1.49
|
%
|
|||||||||
Pharmaceuticals — 22.30%
|
|||||||||||
142,229
|
Novartis AG
|
14,307,953
|
11.35
|
%
|
|||||||
One of the leading
|
|||||||||||
manufacturers of
|
|||||||||||
branded and generic
|
|||||||||||
pharmaceutical products.
|
|||||||||||
(Cost $7,366,895)
|
|||||||||||
45,177
|
Roche Holding AG
|
13,810,886
|
10.95
|
%
|
|||||||
Develops and manufactures
|
|||||||||||
pharmaceutical and
|
|||||||||||
diagnostic products.
|
|||||||||||
Produces prescription
|
|||||||||||
drugs to treat
|
|||||||||||
cardiovascular, infectious
|
|||||||||||
and autoimmune diseases
|
|||||||||||
and for other areas
|
|||||||||||
including dermatology
|
|||||||||||
and oncology.
|
|||||||||||
(Cost $8,109,729)
|
|||||||||||
28,118,839
|
22.30
|
%
|
|||||||||
Private Equity — 2.19%
|
|||||||||||
2,928
|
Partners Group Holding AG
|
2,754,379
|
2.19
|
%
|
|||||||
A global private markets
|
|||||||||||
investment management
|
|||||||||||
firm with investment
|
|||||||||||
programs under
|
|||||||||||
management in private
|
|||||||||||
equity, private real estate,
|
|||||||||||
private infrastructure and
|
|||||||||||
private debt. The firm
|
|||||||||||
manages a broad range of
|
|||||||||||
customized portfolios for
|
|||||||||||
an international clientele
|
|||||||||||
of institutional investors.
|
|||||||||||
Partners Group is
|
|||||||||||
headquartered in
|
|||||||||||
Zug, Switzerland.
|
|||||||||||
(Cost $2,512,468)
|
|||||||||||
2,754,379
|
2.19
|
%
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Common Stock — (continued)
|
|||||||||||
Retail — 6.66%
|
|||||||||||
43,104
|
Cie Financiere
|
||||||||||
Richemont SA
|
$
|
7,306,457
|
5.80
|
%
|
|||||||
Manufactures and retails
|
|||||||||||
luxury goods. Produces
|
|||||||||||
jewelry, watches, leather
|
|||||||||||
goods, writing instruments
|
|||||||||||
and men’s and
|
|||||||||||
women’s wear.
|
|||||||||||
(Cost $3,305,992)
|
|||||||||||
19,807
|
Swatch Group AG –
|
||||||||||
Registered Shares
|
1,088,151
|
0.86
|
%
|
||||||||
Manufactures finished
|
|||||||||||
watches, movements and
|
|||||||||||
components. Produces
|
|||||||||||
components necessary to
|
|||||||||||
its various watch brand
|
|||||||||||
companies. The company
|
|||||||||||
also operates retail boutiques.
|
|||||||||||
(Cost $1,353,585)
|
|||||||||||
8,394,608
|
6.66
|
%
|
|||||||||
Semiconductors — 0.55%
|
|||||||||||
95,940
|
ams-OSRAM AG1
|
690,824
|
0.55
|
%
|
|||||||
Designs and manufactures
|
|||||||||||
advanced sensor solutions.
|
|||||||||||
The company also delivers
|
|||||||||||
a broad range of technology
|
|||||||||||
solutions for consumer
|
|||||||||||
electronics and
|
|||||||||||
communication device
|
|||||||||||
manufactures.
|
|||||||||||
(Cost $1,266,338)
|
|||||||||||
690,824
|
0.55
|
%
|
|||||||||
Transportation — 1.60%
|
|||||||||||
6,802
|
Kuehne + Nagel
|
||||||||||
International AG
|
2,012,507
|
1.60
|
%
|
||||||||
Transports freight
|
|||||||||||
worldwide. The company
|
|||||||||||
operates sea, land, and
|
|||||||||||
rail freight transportation
|
|||||||||||
businesses and
|
|||||||||||
warehousing and
|
|||||||||||
distribution facilities.
|
|||||||||||
(Cost $1,848,698)
|
|||||||||||
2,012,507
|
1.60
|
%
|
|||||||||
Total Common Stock
|
|||||||||||
(Cost $82,764,652)
|
121,378,355
|
96.28
|
%
|
||||||||
Preferred Stock — 0.03%
|
|||||||||||
Industrial Goods & Services — 0.03%
|
|||||||||||
500,863
|
SelFrag AG Class A1,2,3
|
35,270
|
0.03
|
%
|
|||||||
Designs, manufactures and
|
|||||||||||
sells industrial machines
|
|||||||||||
and processes using
|
|||||||||||
selective fragmentation
|
|||||||||||
technology.
|
|||||||||||
(Cost $1,932,198)
|
|||||||||||
35,270
|
0.03
|
%
|
|||||||||
Total Preferred Stock
|
|||||||||||
(Cost $1,932,198)
|
35,270
|
0.03
|
%
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
Percent
|
|||||||||||
No. of
|
of Net
|
||||||||||
Shares
|
Security
|
Value
|
Assets
|
||||||||
Limited Partnership — 0.91%
|
|||||||||||
Biotechnology — 0.91%
|
|||||||||||
3,294,705
|
Aravis Biotech II,
|
||||||||||
Limited Partnership1,3,4
|
$
|
1,151,904
|
0.91
|
%
|
|||||||
Makes early stage
|
|||||||||||
venture investments
|
|||||||||||
in the biotechnology &
|
|||||||||||
pharmaceuticals industry.
|
|||||||||||
(Cost $213,885)
|
|||||||||||
1,151,904
|
0.91
|
%
|
|||||||||
Total Limited Partnership
|
|||||||||||
(Cost $213,885)
|
1,151,904
|
0.91
|
%
|
||||||||
Short-Term Investment — 0.28%
|
|||||||||||
352,358
|
U.S. Bank Money
|
||||||||||
Market Deposit
|
|||||||||||
Account, 1.55%5
|
352,358
|
0.28
|
%
|
||||||||
(Cost $352,358)
|
|||||||||||
352,358
|
0.28
|
%
|
|||||||||
Total Short-Term
|
|||||||||||
Investment
|
|||||||||||
(Cost $352,358)
|
352,358
|
0.28
|
%
|
||||||||
Total Investments6
|
|||||||||||
(Cost $85,263,093)
|
122,917,887
|
97.50
|
%
|
||||||||
Other Assets
|
|||||||||||
Less Liabilities6
|
3,149,241
|
2.50
|
%
|
||||||||
Net Assets
|
$
|
126,067,128
|
100.00
|
%
|
|||||||
Net Asset Value Per Share:
|
|||||||||||
($126,067,128 ÷
|
|||||||||||
shares outstanding,
|
|||||||||||
$0.001 par value:
|
|||||||||||
shares authorized)
|
|
|
$ |
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
1
|
Non-income producing security.
|
2
|
Value determined using significant unobservable inputs.
|
3
|
Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value
in accordance with the Fund’s valuation policy and procedures. At the end of the period, the aggregate Fair Value of these securities amounted to $2,547,371 or 2.02% of the Fund’s net assets. Additional information on these securities is as
follows:
|
Security
|
Acquisition Date
|
Cost
|
||||
Aravis Biotech II, Limited Partnership
|
July 31, 2007 – May 29, 2018
|
$
|
213,885
|
|||
Eyesense AG – Common Shares
|
July 22, 2010 – October 3, 2011
|
3,007,048
|
||||
SelFrag AG – Class A – Preferred Shares
|
December 15, 2011 – January 28, 2014
|
1,932,198
|
||||
Spineart SA – Common Shares
|
December 22, 2010 - December 20, 2020
|
1,554,486
|
||||
$
|
6,707,617
|
4
|
Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company’s outstanding voting securities or an equivalent interest
in the company. Details related to affiliated company holdings are as follows:
|
Value
|
Change in
|
Value
|
||||||||||||||||||||||||||||||
as of
|
Gross
|
Gross
|
Realized
|
Unrealized
|
Corporate
|
Interest
|
as of
|
|||||||||||||||||||||||||
Name of Issuer
|
12/31/22
|
Additions
|
Reductions
|
Gain/(Loss)
|
Gain/(Loss)
|
Actions
|
Income
|
6/30/23
|
||||||||||||||||||||||||
Aravis Biotech II,
|
||||||||||||||||||||||||||||||||
Limited Partnership
|
$
|
1,302,142
|
$
|
—
|
$
|
—
|
$
|
217,940
|
$
|
1,446,061
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
1,151,904
|
|||||||||||||||
$
|
1,302,142
|
$
|
—
|
$
|
—
|
$
|
217,940
|
$
|
1,446,061
|
$
|
(1,814,239
|
)
|
$
|
—
|
$
|
1,151,904
|
5
|
Rate shown is the seven day annualized yield as of June 30, 2023.
|
6
|
All of the Fund’s investments and other assets are pledged as collateral in accordance with a credit agreement with U.S. Bank, National Association.
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2023
|
PORTFOLIO HOLDINGS
|
|
% of Net Assets as of June 30, 2023
|
|
Pharmaceuticals
|
22.30%
|
Food
|
21.40%
|
Insurance
|
8.98%
|
Retail
|
6.66%
|
Healthcare-Products
|
6.07%
|
Diversified Financial Services
|
3.85%
|
Biotechnology
|
3.54%
|
Building Materials
|
3.41%
|
Banks
|
2.61%
|
Private Equity
|
2.19%
|
Electronic Components & Equipment
|
2.15%
|
Industrials
|
2.08%
|
Electric
|
2.06%
|
Computers
|
1.82%
|
Transportation
|
1.60%
|
Chemicals
|
1.50%
|
Packaging & Containers
|
1.49%
|
Metal Fabricate/Hardware
|
1.23%
|
Healthcare-Services
|
0.72%
|
Semiconductors
|
0.55%
|
Machinery-Diversified
|
0.50%
|
Advertising
|
0.48%
|
Short-Term Investment
|
0.28%
|
Industrial Goods & Services
|
0.03%
|
Other Assets Less Liabilities
|
2.50%
|
100.00%
|
|
TOP 10 PORTFOLIO HOLDINGS
|
|
% of Net Assets as of June 30, 2023
|
|
Nestle SA
|
18.49%
|
Novartis AG
|
11.35%
|
Roche Holding AG
|
10.95%
|
Cie Financiere Richemont SA
|
5.80%
|
Zurich Insurance Group AG
|
4.31%
|
Lonza Group AG
|
2.39%
|
UBS Group AG
|
2.23%
|
Partners Group Holding AG
|
2.18%
|
BKW AG
|
2.06%
|
Baloise Holding AG
|
2.04%
|
Statement of Assets and Liabilities (Unaudited)
|
June 30, 2023
|
Assets:
|
||||
Investments in unaffiliated issuers, at value (cost $85,049,208)
|
$
|
121,765,983
|
||
Investments in affiliated issuers, at value (cost $213,885)
|
1,151,904
|
|||
Total Investments, at value (cost $85,263,093)
|
122,917,887
|
|||
Foreign currency (cost $3,656,664)
|
3,704,886
|
|||
Tax reclaims receivable
|
1,311,565
|
|||
Interest receivable
|
3,561
|
|||
Prepaid expenses
|
38,490
|
|||
Total assets
|
127,976,389
|
|||
Liabilities:
|
||||
Accrued Fees and Expenses:
|
||||
Payable for investments purchased
|
1,622,152
|
|||
Investment advisory
|
74,974
|
|||
Directors
|
73,477
|
|||
Legal
|
55,483
|
|||
Audit
|
27,512
|
|||
Custody
|
2,411
|
|||
Other
|
53,252
|
|||
Total liabilities
|
1,909,261
|
|||
Net assets
|
$
|
126,067,128
|
||
Composition of Net Assets:
|
||||
Paid-in capital
|
88,897,845
|
|||
Total distributable earnings
|
37,169,283
|
|||
Net assets
|
$
|
126,067,128
|
||
Net Asset Value Per Share:
|
||||
($126,067,128 ÷
shares outstanding, |
||||
$0.001 par value:
shares authorized) |
$
|
|
Statement of Operations (Unaudited)
|
For the Six Months Ended June 30, 2023
|
Investment Income:
|
||||
Dividend (less of foreign tax withheld of $459,257)
|
$
|
2,744,194
|
||
Interest income
|
27,386
|
|||
Total income
|
2,771,580
|
|||
Expenses:
|
||||
Investment advisory fees (Note 2)
|
431,615
|
|||
Directors’
|
155,026
|
|||
Legal (Note 3)
|
107,578
|
|||
Officer
|
67,173
|
|||
Administration (Note 3)
|
62,615
|
|||
Delaware franchise tax (Note 9)
|
61,500
|
|||
Printing and shareholder reports
|
34,210
|
|||
Audit (Note 3)
|
27,512
|
|||
Custody (Note 3)
|
25,349
|
|||
Insurance
|
24,647
|
|||
Transfer agency (Note 3)
|
16,354
|
|||
Commitment fee (Note 9)
|
10,487
|
|||
Miscellaneous
|
10,200
|
|||
Total expenses
|
1,034,266
|
|||
Net investment income
|
1,737,314
|
|||
Realized and Unrealized Gains on Investments and Foreign Currency Translations:
|
||||
Net realized gain from:
|
||||
Investments in unaffiliated issuers
|
86,390
|
|||
Foreign currency transactions
|
191,590
|
|||
Total net realized gain from unaffiliated and
|
||||
affiliated issuers and foreign currency transactions
|
277,980
|
|||
Net change in unrealized appreciation from:
|
||||
Investments in unaffiliated issuers
|
11,259,227
|
|||
Investments in affiliated issuers
|
1,446,061
|
|||
Foreign currency translations
|
76,551
|
|||
Total net change in unrealized appreciation from
|
||||
unaffiliated and affiliated issuers, and foreign currency translations
|
12,781,839
|
|||
Net Realized and Unrealized Gain on
|
||||
Investments and Foreign Currency Translations
|
13,059,819
|
|||
Net Increase in Net Assets from Operations
|
$
|
14,797,133
|
Statement of Cash Flows (Unaudited)
|
For the Six Months Ended June 30, 2023
|
Cash flows from operating activities:
|
||||
Net increase in net assets applicable to common shareholders
|
$
|
14,797,133
|
||
Adjustments to reconcile net increase in net assets applicable to
|
||||
common shareholders resulting from operations to net cash
|
||||
provided by operating activities:
|
||||
Purchases of investments
|
(6,507,419
|
)
|
||
Proceeds from sales of investments
|
9,435,766
|
|||
Net purchases and sales of short-term investments
|
(21,328
|
)
|
||
Return of capital distributions received from underlying investments
|
1,603,805
|
|||
Increase in tax reclaims receivable
|
(13,677
|
)
|
||
Increase in dividends and interest receivable
|
(614
|
)
|
||
Increase in other assets
|
(18,054
|
)
|
||
Increase in payable for investments purchased
|
1,622,152
|
|||
Increase in payable to Adviser
|
4,717
|
|||
Decrease in accrued expenses and other liabilities
|
(42,023
|
)
|
||
Net realized gains from investments
|
(86,390
|
)
|
||
Net change in unrealized appreciation (depreciation) from investments
|
(12,705,288
|
)
|
||
Net cash provided by operating activities
|
8,068,780
|
|||
Cash flows from financing activities:
|
||||
Distributions paid to common shareholders
|
(3,216,720
|
)
|
||
Repurchase of common stock
|
(1,687,598
|
)
|
||
Net cash used in financing activities
|
(4,904,318
|
)
|
||
Net change in cash
|
$
|
3,164,462
|
||
Cash:
|
||||
Beginning of period*
|
540,424
|
|||
End of period*
|
$
|
3,704,886
|
||
Cash financing activities not included herein consist of interest paid
|
10,487
|
For the
|
||||||||
Six Months Ended
|
For the
|
|||||||
June 30, 2023
|
Year Ended
|
|||||||
(Unaudited)
|
December 31, 2022
|
|||||||
Increase (Decrease) in Net Assets:
|
||||||||
Operations:
|
||||||||
Net investment income
|
$
|
1,737,314
|
$
|
920,814
|
||||
Total net realized gain from unaffiliated and
|
||||||||
affiliated issuers and foreign currency transactions
|
277,980
|
2,080,182
|
||||||
Total net change in unrealized appreciation
|
||||||||
(depreciation) from unaffiliated and affiliated issuers,
|
||||||||
foreign currency and foreign currency translations
|
12,781,839
|
(30,399,182
|
)
|
|||||
Net increase (decrease) in net assets from operations
|
14,797,133
|
(27,398,186
|
)
|
|||||
Distributions to Stockholders:
|
||||||||
From earnings
|
(3,216,720
|
)
|
(2,977,194
|
)
|
||||
From return of capital
|
—
|
(5,241,653
|
)
|
|||||
Total distributions to stockholders
|
(3,216,720
|
)
|
(8,218,847
|
)
|
||||
Capital Stock Transactions:
|
||||||||
Value of shares repurchased through
|
||||||||
stock repurchase program (Note 6)
|
(1,687,598
|
)
|
(120,928
|
)
|
||||
Total decrease from capital share transactions
|
(1,687,598
|
)
|
(120,928
|
)
|
||||
Total increase (decrease) in net assets
|
9,892,815
|
(35,737,961
|
)
|
|||||
Net Assets:
|
||||||||
Beginning of period
|
116,174,313
|
151,912,274
|
||||||
End of period
|
$
|
126,067,128
|
$
|
116,174,313
|
For the Six
|
||||||||||||||||||||||||
Months Ended
|
||||||||||||||||||||||||
June 30, 2023
|
For the Years Ended December 31,
|
|||||||||||||||||||||||
(Unaudited)
|
2022
|
2021
|
2020
|
2019
|
2018
|
|||||||||||||||||||
Per Share Operating Performance:
|
||||||||||||||||||||||||
Net asset value at the beginning of period
|
$
|
8.80
|
$
|
11.50
|
$
|
10.45
|
$
|
9.71
|
$
|
7.96
|
$
|
14.10
|
||||||||||||
Income from Investment Operations:
|
||||||||||||||||||||||||
Net investment income1
|
0.13
|
0.07
|
0.05
|
0.05
|
0.01
|
0.14
|
||||||||||||||||||
Net realized and unrealized
|
||||||||||||||||||||||||
gain (loss) on investments2
|
0.98
|
(2.15
|
)
|
1.58
|
1.24
|
1.88
|
(1.35
|
)
|
||||||||||||||||
Total from investment activities
|
1.11
|
(2.08
|
)
|
1.63
|
1.29
|
1.89
|
(1.21
|
)
|
||||||||||||||||
Gain from tender offer
|
—
|
—
|
—
|
—
|
—
|
0.30
|
4
|
|||||||||||||||||
Capital change resulting from
|
||||||||||||||||||||||||
the issuance of fund shares
|
—
|
—
|
—
|
—
|
—
|
(0.12
|
)4
|
|||||||||||||||||
Anti-dilutive effect of common
|
||||||||||||||||||||||||
share repurchase program
|
0.03
|
0.00
|
5
|
—
|
0.01
|
—
|
—
|
|||||||||||||||||
Less Distributions:
|
||||||||||||||||||||||||
Net investment income
|
(0.24
|
)
|
(0.06
|
)
|
(0.06
|
)
|
(0.08
|
)
|
(0.12
|
)
|
(0.10
|
)
|
||||||||||||
Net realized gains
|
—
|
(0.16
|
)
|
(0.09
|
)
|
—
|
(0.02
|
)
|
(5.01
|
)
|
||||||||||||||
Return of Capital
|
—
|
(0.40
|
)
|
(0.43
|
)
|
(0.48
|
)
|
—
|
—
|
|||||||||||||||
Total distributions
|
(0.24
|
)
|
(0.62
|
)
|
(0.58
|
)
|
(0.56
|
)
|
(0.14
|
)
|
(5.11
|
)
|
||||||||||||
Net asset value at end of period
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Market value per share at the end of period
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Total Investment Returns:3,6
|
||||||||||||||||||||||||
Based on market value per share
|
12.16
|
%
|
-17.62
|
%
|
18.25
|
%
|
14.18
|
%
|
24.00
|
%
|
-10.90
|
%
|
||||||||||||
Based on net asset value per share
|
13.16
|
%
|
-17.97
|
%
|
16.09
|
%
|
14.29
|
%
|
23.80
|
%
|
-6.98
|
%
|
||||||||||||
Ratios to Average Net Assets:7
|
||||||||||||||||||||||||
Net expenses
|
1.68
|
%9
|
1.68
|
%8
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
1.44
|
%
|
||||||||||||
Gross expenses
|
1.68
|
%9
|
1.68
|
%8
|
1.40
|
%
|
1.80
|
%
|
2.13
|
%
|
1.44
|
%
|
||||||||||||
Net investment income
|
2.82
|
%
|
0.74
|
%
|
0.48
|
%
|
0.48
|
%
|
0.10
|
%
|
1.12
|
%
|
||||||||||||
Supplemental Data and Ratios
|
||||||||||||||||||||||||
Net assets at end of period (000’s)
|
$
|
126,067
|
$
|
116,174
|
$
|
151,912
|
$
|
138,040
|
$
|
128,864
|
$
|
105,577
|
||||||||||||
Average net assets during the period (000’s)
|
$
|
124,341
|
$
|
123,684
|
$
|
144,019
|
$
|
125,666
|
$
|
118,960
|
$
|
305,270
|
||||||||||||
Portfolio turnover rate
|
5
|
%
|
15
|
%
|
11
|
%
|
12
|
%
|
18
|
%
|
21
|
%
|
1
|
Calculated using the average shares method.
|
2
|
Includes net realized and unrealized currency gains and losses.
|
3
|
Total investment return based on market value differs from total investments return based on net asset value due to changes in the relationship between the market value of
the Fund’s shares and its NAV per share.
|
4
|
On November 20, 2018, the Fund accepted for cash purchase 24,638,918 shares of the Fund’s common stock at a price equal to $7.86 per share, which represented 98% of the
Fund’s NAV per share of $8.02 as of the close of the regular trading session of the New York Stock Exchange on November 19, 2018. As a result of the purchase of the 24,638,918 shares, the Fund had 13,267,111 shares of common stock outstanding
as of November 20, 2018.
|
5
|
Less than 0.5 cents per share.
|
6
|
Not annualized for years less than one year.
|
7
|
Annualized for years less than one year.
|
8
|
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.05% for the year ended December 31, 2022.
|
9
|
If commitment fees had been excluded, the expense ratios would have been lower by 0.02% for the six months ended June 30, 2023.
|
Level 1—
|
unadjusted quoted prices in active markets for identical assets and liabilities
|
Level 2—
|
other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)
|
Level 3—
|
significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)
|
Level 2
|
Level 3
|
Investments
|
||||||||||||||||||
Level 1
|
Other Significant
|
Significant
|
Valued at
|
|||||||||||||||||
Quoted Prices
|
Observable Inputs
|
Unobservable Inputs
|
NAV**
|
Total
|
||||||||||||||||
Investments in Securities*
|
||||||||||||||||||||
Common Stock
|
$
|
120,018,158
|
$
|
—
|
$
|
1,360,197
|
$
|
—
|
$
|
121,378,355
|
||||||||||
Preferred Stock
|
—
|
—
|
35,270
|
—
|
35,270
|
|||||||||||||||
Limited Partnership
|
—
|
—
|
—
|
1,151,904
|
1,151,904
|
|||||||||||||||
Money Market Deposit Account
|
—
|
352,358
|
—
|
—
|
352,358
|
|||||||||||||||
Total Investments in Securities
|
$
|
120,018,158
|
$
|
352,358
|
$
|
1,395,467
|
$
|
1,151,904
|
$
|
122,917,887
|
*
|
Please see the Schedule of Investments for industry classifications.
|
**
|
As of June 30, 2023, certain of the Fund’s investments were valued using net asset value (“NAV”) per share (or its equivalent) as a practical expedient for fair value and
have been excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented
in the statement of assets and liabilities.
|
Value at
|
|||||||||
June 30, 2023
|
Valuation Technique
|
Unobservable Inputs
|
Range1
|
||||||
Healthcare-Products
|
|||||||||
EyeSense AG, Series A—Common Shares
|
$
|
50,466
|
Market approach
|
Latest round of financing with
|
70-90%
|
|
|||
an additional discount as a
|
|||||||||
going concern using a
|
|||||||||
probability weighted approach
|
|||||||||
Spineart SA—Common Shares
|
1,309,731
|
Market approach
|
Based on listed trading
|
15-25%
|
|
||||
multiples, cross checked to
|
|||||||||
secondary share purchase
|
|||||||||
with additional discount for
|
|||||||||
lack of marketability
|
|||||||||
Industrial Goods & Services
|
|||||||||
SelFrag AG Class A—Preferred Shares
|
35,270
|
Market approach
|
Latest round of financing
|
||||||
with an additional discount
|
|||||||||
for lack of marketability
|
40-60%
|
|
|||||||
Total
|
$
|
1,395,467
|
1
|
Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. A change in the discount rate is accompanied by a
directionally opposite change in fair value.
|
Common
|
Preferred
|
|||||||||||
Stock
|
Stock
|
Total
|
||||||||||
Balance as of December 31, 2022
|
$
|
1,384,260
|
$
|
48,722
|
$
|
1,432,982
|
||||||
Change in Unrealized Appreciation/Depreciation
|
(24,063
|
)
|
(13,452
|
)
|
(37,515
|
)
|
||||||
Net Realized Gain (Loss)
|
—
|
—
|
—
|
|||||||||
Gross Purchases
|
—
|
—
|
—
|
|||||||||
Gross Sales
|
—
|
—
|
—
|
|||||||||
Transfer out of Level 3
|
—
|
—
|
—
|
|||||||||
Balance as of June 30, 2023
|
$
|
1,360,197
|
$
|
35,270
|
$
|
1,395,467
|
||||||
Change in unrealized appreciation (depreciation) during the period
|
||||||||||||
for Level 3 investments held at June 30, 2023
|
(24,063
|
)
|
(13,452
|
)
|
(37,515
|
)
|
For the Period Ended
|
For the Year Ended
|
|||||||||||||||
June 30, 2023
|
December 31, 2022
|
|||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||
Dividends Reinvested
|
—
|
$
|
—
|
—
|
$
|
—
|
||||||||||
Repurchased through Stock Repurchase Program (Note 6)
|
(205,045
|
)
|
(1,687,598
|
)
|
(16,504
|
)
|
(120,928
|
)
|
||||||||
Repurchased from Tender Offer (Note 7)
|
—
|
—
|
—
|
—
|
||||||||||||
Net Increase/(Decrease)
|
(205,045
|
)
|
$
|
(1,687,598
|
)
|
(16,504
|
)
|
$
|
(120,928
|
)
|
2022
|
2021
|
|||||||
Ordinary Income
|
$
|
810,137
|
$
|
907,509
|
||||
Return of Capital
|
5,241,653
|
5,667,420
|
||||||
Long-Term Capital Gains
|
2,167,057
|
1,076,948
|
||||||
Total
|
$
|
8,218,847
|
$
|
7,651,877
|
Tax cost of investments
|
$
|
88,977,674
|
||
Unrealized appreciation
|
37,699,931
|
|||
Unrealized depreciation
|
(12,040,572
|
)
|
||
Net unrealized appreciation
|
25,659,359
|
|||
Net unrealized on foreign currency
|
4,375
|
|||
Undistributed ordinary income
|
—
|
|||
Undistributed long-term capital gains
|
—
|
|||
Distributable earnings
|
—
|
|||
Other accumulated losses
|
(74,864
|
)
|
||
Total distributable earnings
|
$
|
25,588,870
|
Record Date
|
Payable Date
|
Ordinary Income
|
Return of Capital
|
ST Cap Gains
|
LT Cap Gains
|
Total Distribution
|
||||||||||||||||
3/22/22
|
3/31/22
|
$
|
0.01641201
|
$
|
0.10618706
|
$
|
—
|
$
|
0.04390093
|
$
|
0.16650
|
|||||||||||
6/21/22
|
6/30/22
|
0.01641201
|
0.10618706
|
—
|
0.04390093
|
0.16650
|
||||||||||||||||
9/21/22
|
9/30/22
|
0.01641201
|
0.10618706
|
—
|
0.04390093
|
0.16650
|
||||||||||||||||
12/20/22
|
12/30/22
|
0.01210940
|
0.07834883
|
—
|
0.03239176
|
0.12285
|
||||||||||||||||
$
|
0.62235
|
Original Capital
|
Unfunded
|
|
Investments
|
Commitment*
|
Commitment*
|
Private Equity Limited Partnership—International(a)
|
||
Aravis Biotech II, Limited Partnership
|
$3,632,706
|
$ —
|
*
|
The original capital commitment represents 3,250,000 Swiss francs, which has been fully funded as of December 31, 2022. The Swiss franc/U.S. dollar exchange rate as of June
30, 2023 was used for conversion and equaled 0.89465 as of such date.
|
(a)
|
This category consists of one private equity limited partnership that invests primarily in venture capital companies in the biotechnology and medical technology sectors.
There is no redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.
|
Weighted
|
|||||
Maximum Amount
|
Average Daily
|
Maximum Amount
|
Interest
|
Commitment
|
Average
|
Available
|
Borrowings
|
Outstanding
|
Expense
|
Fee
|
Interest Rate
|
$15,000,000
|
$0
|
$0
|
$0
|
$10,487
|
N/A
|
Gross Foreign
|
Foreign Taxes
|
Gross Foreign
|
Foreign Taxes
|
Shares Outstanding
|
Source Income
|
Pass-through
|
Source Income Per Share
|
Pass-through Per Share
|
at 12/31/22
|
$3,473,999
|
$489,567
|
$0.26326651
|
$0.03710035
|
13,195,750
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class I
|
|||
Richard Dayan
|
Director (2018);
|
President and owner of
|
Trustee of High Income Securities
|
Member of the
|
Cactus Trading since 1990
|
Fund since 2018
|
|
Age: 79
|
Audit Committee (2018);
|
||
Member of the
|
|||
Governance/
|
|||
Nominating
|
|||
Committee (2018)
|
|||
Moritz A. Sell
|
Director (2017);
|
Principal, Edison Holdings GmbH;
|
Trustee of High Income Securities
|
Member and
|
Senior Advisor, Markston
|
Fund since 2018; Director of FAX
|
|
Age: 55
|
Chair of the Audit
|
International LLC until 2019; Director,
|
(Aberdeen Asia Pacific Income
|
Committee (2017);
|
Market Strategist and Head of
|
Fund) and FCO (Aberdeen Global
|
|
Lead Independent
|
Proprietary Trading (London Branch),
|
Income Fund) since 2018; Director of
|
|
Director (2018)
|
Landesbank Berlin AG and
|
IAF (Aberdeen Australia Equity Fund)
|
|
Landesbank Berlin Holding AG
|
since 2004; Director of Aberdeen
|
||
(formerly, Bankgesellschaft Berlin AG)
|
Greater China Fund until 2018;
|
||
from 1996 to 2013
|
Chairman and Director of
|
||
Aberdeen Singapore Fund
|
|||
until 2018
|
|||
Class II
|
|||
Andrew Dakos*
|
Director
|
Partner, Bulldog Investors, LLP;
|
President and Director of Special
|
(2017) and
|
Partner, Ryan Heritage, LLP;
|
Opportunities Fund, Inc. since
|
|
Age: 57
|
Chairman (2018)
|
Principal of the former general partner
|
2009; Trustee, Crossroads
|
of several private investment
|
Liquidating Trust (formerly,
|
||
partnerships in the Bulldog
|
Crossroads Capital, Inc.) from
|
||
Investors group of private funds;
|
2015-2020; President and Trustee of
|
||
Principal of the managing general
|
High Income Securities Fund since
|
||
partner of Bulldog Investors
|
2018; Director, Brookfield DTLA
|
||
General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017
|
*
|
Mr. Dakos is considered an “interested person” of the Fund within the meaning of the 1940 Act (and a Class II Interested Director of the Fund) as a result of his position as
President and Chief Executive Officer of the Fund.
|
Position(s)
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Held By Director
|
Address1 & Age
|
(Since)
|
During At Least The Past Five Years
|
During At Least The Past Five Years
|
Class III
|
|||
Phillip F. Goldstein
|
Director (2018);
|
Partner of Bulldog Investors, LLP
|
Chairman and Director of The
|
Member and
|
since 2009; Partner of Ryan
|
Mexico Equity and Income Fund,
|
|
Age: 78
|
Chair of the
|
Heritage, LLP; Principal of the former
|
Inc. since 2000; Chairman,
|
Governance/
|
general partner of several private
|
Director and Secretary of Special
|
|
Nominating
|
investment partnerships in the
|
Opportunities Fund, Inc. since
|
|
Committee (2018)
|
Bulldog Investors group of private
|
2009; Chairman, Trustee and Secretary
|
|
funds since 2009; Principal of the
|
of High Income Securities Fund since
|
||
managing general partner of
|
2018; Director of Brookfield DTLA
|
||
Bulldog Investors General Partnership
|
Fund Office Trust Investor Inc.
|
||
since 2017; MVC Capital, Inc. from
|
|||
2012-2020; Trustee of Crossroads
|
|||
Liquidating Trust (formerly,
|
|||
Crossroads Capital, Inc.) from
|
|||
2016-2020
|
|||
Gerald Hellerman
|
Director (2018);
|
Chief Compliance Officer of
|
Director of Mexico Equity and
|
Member of the
|
The Mexico Equity and Income Fund,
|
Income Fund, Inc. since 2001;
|
|
Age: 85
|
Audit Committee
|
Inc. from 2001 through March 31,
|
Special Opportunities Fund, Inc.
|
(2018); Member
|
2020 and Special Opportunities
|
since 2009; Fiera Capital Series Trust
|
|
and Chair of the
|
Fund, Inc. from 2009 through
|
since 2017; Trustee of High
|
|
Pricing Committee
|
March 31, 2020; Managing Director
|
Income Securities Fund since 2018;
|
|
(2018)
|
of Hellerman Associates (a financial
|
MVC Capital, Inc. from
|
|
and corporate consulting firm)
|
2003-2020; Trustee of Crossroads
|
||
since 1993 (which terminated
|
Liquidating Trust (formerly, Crossroads
|
||
activities as of December 31, 2013)
|
Capital, Inc.) from 2017-2020
|
Officers2
|
|||
Name,
|
Position(s)
|
Term of Office and
|
Principal Occupation(s)
|
Address1 & Age
|
with Fund
|
Length of Time Served
|
During At Least The Past Five Years
|
Andrew Dakos
|
President and
|
President and Chief
|
Partner, Bulldog Investors, LLP;
|
Chief Executive
|
Executive Officer since 2019;
|
Partner, Ryan Heritage, LLP;
|
|
Age: 57
|
Officer; Director
|
Chairman since 2018;
|
Principal of the former general
|
and Chairman.
|
Director since 2017
|
partner of several private
|
|
investment partnerships in the
|
|||
Bulldog Investors group of private
|
|||
funds; Principal of the managing
|
|||
general partner of Bulldog
|
|||
Investors General Partnership
|
|||
Thomas Antonucci
|
Chief Financial
|
Since 2019
|
Director of Operations,
|
Officer
|
Bulldog Investors, LLP;
|
||
Age: 54
|
Chief Financial Officer
|
||
and Treasurer of Special
|
|||
Opportunities Fund; Treasurer
|
|||
of High Income Securities Fund
|
|||
Stephanie Darling
|
Chief Compliance
|
Since 2019
|
General Counsel and Chief
|
Officer
|
Compliance Officer of Bulldog
|
||
Age: 53
|
Investors, LLP; Chief Compliance
|
||
Officer of Ryan Heritage, LLP,
|
|||
High Income Securities
|
|||
Fund, Special Opportunities Fund,
|
|||
Inc., and Mexico Equity and
|
|||
Income Fund, Inc.; Principal of The
|
|||
Law Office of Stephanie Darling;
|
|||
Editor-in-Chief of The
|
|||
Investment Lawyer
|
|||
Rajeev Das
|
Secretary
|
Since 2019
|
Head of Trading, Bulldog
|
Investors, LLP
|
|||
Age: 54
|
1
|
The address for each Director and Executive Officer is c/o The Swiss Helvetia Fund, Inc., 615 East Michigan Street, Milwaukee, WI 53202.
|
2
|
Each Executive Officer serves on a year-to-year basis for an indefinite term, until his or her successor is elected and qualified.
|
Andrew Dakos
|
Gerald Hellerman1,4
|
Chairman, President and
|
Director
|
Chief Executive Officer
|
Thomas Antonucci
|
Richard Dayan1,5
|
Chief Financial Officer
|
Director
|
Stephanie Darling
|
Phillip Goldstein2
|
Chief Compliance Officer
|
Director
|
Rajeev Das
|
Moritz Sell3,6
|
Secretary
|
Director
|
1
|
Audit Committee Member
|
4
|
Pricing Committee Chair
|
2
|
Governance Nominating
|
5
|
Governance Committee
|
Committee Chair
|
Member
|
||
3
|
Audit Committee Chair
|
6
|
Lead Independent Director
|
Period
|
(a)
Total Number of
Shares (or Units)
Purchased
|
(b)
Average Price Paid
per Share (or Unit) |
(c)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
|
(d)
Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
|
1/1/23 – 1/31/23
|
N/A
|
N/A
|
N/A
|
N/A
|
2/1/23 – 2/28/23
|
4,510
|
7.80
|
N/A
|
N/A
|
3/1/23 – 3/31/23
|
8,168
|
7.71
|
N/A
|
N/A
|
4/1/23 – 4/30/23
|
177,533
|
8.24
|
N/A
|
N/A
|
5/1/23 – 5/31/23
|
12,649
|
8.34
|
N/A
|
N/A
|
6/1/23 – 6/30/23
|
2,185
|
8.07
|
N/A
|
N/A
|
Total
|
205,045
|
8.06
|
N/A
|
N/A
|
(a)
|
The Registrant’s President and Chief Executive Officer and Chief Financial Officer have reviewed the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as
of a date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d‑15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the
disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and
by the Registrant’s service provider.
|
(b)
|
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the second fiscal quarter of the period covered by this report that have materially
affected, or are reasonably likely to materially affect, the Registrant's internal control over financial reporting.
|
(a)
|
(1) Any code of ethics or amendment thereto, that is the subject of the disclosure required by Item 2, to the extent that the registrant intends to satisfy Item 2 requirements through filing an
exhibit. Not applicable.
|
1.
|
I have reviewed this report on Form N-CSR of The Swiss Helvetia Fund, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the second fiscal quarter of
the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
|
Date: 8/29/2023
|
/s/Andrew Dakos
Andrew Dakos
President and Chief Executive Officer |
1.
|
I have reviewed this report on Form N-CSR of The Swiss Helvetia Fund, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the second fiscal quarter of
the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
|
Date: 8/29/2023
|
/s/Thomas Antonucci
Thomas Antonucci Chief Financial Officer
|
/s/Andrew Dakos
Andrew Dakos President and Chief Executive Officer,
The Swiss Helvetia Fund, Inc.
|
/s/Thomas Antonucci
Thomas Antonucci
Chief Financial Officer,
The Swiss Helvetia Fund, Inc.
|
Dated: 8/29/2023
|
Current Distribution |
2023 Fiscal Year*
|
|||
Per Share
Amount
|
% of
Current
Distribution
|
Per Share
Amount
|
% of the 2023
Distributions
|
|
Net Investment Income
|
$0.02840
|
23.12%
|
$0.02840
|
23.12%
|
Net Realized Short-Term Capital Gains
|
$0.00000
|
0.00%
|
$0.00000
|
0.00%
|
Net Realized Long-Term Capital Gains
|
$0.00000
|
0.00%
|
$0.00000
|
0.00%
|
Return of Capital (or other Capital Source)
|
$0.09445
|
76.88%
|
$0.09445
|
76.88%
|
TOTAL
|
$0.12285
|
100.00%
|
$0.12285
|
100.00%
|
Annualized Distribution Rate as a % of NAV*
|
5.42%
|
|
Cumulative Distribution Rate on NAV*
|
0.00%
|
|
Cumulative Total Return on NAV**
|
2.95%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended February 28, 2023***
|
5.50%
|
*
|
Based on the Fund's NAV as of February 28, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through February 28, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
Current Distribution | 2023 Fiscal Year* | |||
Per Share
Amount
|
% of
Current
Distribution
|
Per Share
Amount |
% of the 2023
Distributions
|
|
Net Investment Income
|
$0.10991
|
89.47%
|
$0.13875
|
56.47%
|
Net Realized Short-Term Capital Gains
|
$0.00132
|
1.07%
|
$0.00000
|
0.00%
|
Net Realized Long-Term Capital Gains
|
$0.01162
|
9.46%
|
$0.00000
|
2.77%
|
Return of Capital (or other Capital Source)
|
$0.00000
|
0.00%
|
$0.10015
|
40.76%
|
TOTAL
|
$0.12285
|
100.00%
|
$0.24570
|
100.00%
|
Annualized Distribution Rate as a % of NAV*
|
5.16%
|
|
Cumulative Distribution Rate on NAV*
|
1.29%
|
|
Cumulative Total Return on NAV**
|
9.66%
|
|
Average Annual Total Return (in relation to NAV) for
the five-year period ended May 31, 2023***
|
7.85%
|
*
|
Based on the Fund's NAV as of May 31, 2023.
|
**
|
Cumulative fiscal year-to-date return is based on the change in NAV including distributions paid and assuming reinvestment of these distributions for
the period January 1, 2023 through May 31, 2023.
|
***
|
Average annual total return is based on change in NAV including distributions paid and assuming reinvestment of these distributions and is through the
last business day of the month prior to the month of the current distribution record date.
|
N-2 - $ / shares |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Dec. 31, 2018 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cover [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Entity Central Index Key | 0000813623 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amendment Flag | false | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Document Type | N-CSRS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Entity Registrant Name | Swiss Helvetia Fund, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock [Table Text Block] | Note 4—Capital Share Transactions
The Fund is authorized to issue up to 50 million shares of capital stock. Transactions in capital shares were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Document Period End Date | Jun. 30, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Shares [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Description of Registrant [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share Price | $ 8.22 | $ 8.22 | $ 7.56 | $ 9.94 | $ 8.94 | $ 8.41 | $ 6.90 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NAV Per Share | $ 9.70 | $ 9.70 | $ 8.80 | $ 11.50 | $ 10.45 | $ 9.71 | $ 7.96 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capital Stock, Long-Term Debt, and Other Securities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding Security, Authorized [Shares] | 50,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding Security, Not Held [Shares] | 12,990,705 |
1 Year Swiss Helvetia Chart |
1 Month Swiss Helvetia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions